Return of the megaround: Is biotech back from the brink?

Return of the megaround: Is biotech back from the brink?

Submitted by admin on March 21, 2023 - 10:08am
Source: 
Fierce Biotech
News Tags: 
Rapport Therapeutics
Noema Pharma
Bicara Therapeutics
funding
venture capital
Headline: 
Return of the megaround: Is biotech back from the brink?
snippet: 

$100 million for Rapport Therapeutics. $112 million for Noema Pharma. $108 million for Bicara Therapeutics. The megaround has come roaring back in the past few weeks, but is biotech really healing?

Do Not Allow Advertisers to Use My Personal information